SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001564590-18-009004
Filing Date
2018-04-25
Accepted
2018-04-25 13:38:00
Documents
8
Effectiveness Date
2018-04-25

Document Format Files

Seq Description Document Type Size
1 DEFA14A snss-defa14a_20180606.htm DEFA14A 111288
2 GRAPHIC g2018042322431922217327.jpg GRAPHIC 1362
3 GRAPHIC g2018042322431923317328.jpg GRAPHIC 2391
4 GRAPHIC g2018042322431924617329.jpg GRAPHIC 2391
5 GRAPHIC g2018042322431928417333.jpg GRAPHIC 1035
6 GRAPHIC g2018042322431928117332.jpg GRAPHIC 1063
7 GRAPHIC g2018042322431925217330.jpg GRAPHIC 1062
8 GRAPHIC g2018042322431925517331.jpg GRAPHIC 2391
  Complete submission text file 0001564590-18-009004.txt   129726
Mailing Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 395 OYSTER POINT BOULEVARD SUITE 400 SOUTH SAN FRANCISCO CA 94080 650-266-3500
SUNESIS PHARMACEUTICALS INC (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-51531 | Film No.: 18773714
SIC: 2834 Pharmaceutical Preparations